You are here: Industry Insights > NSCLC

News List

Setback for AZ’ Imfinzi lung cancer combination pharmatimes
November 20, 2018
AstraZeneca’s Imfinzi has failed to show a significant benefit over standard of care (SoC) chemotherapy on overall survival in certain patients with lung cancer.
AstraZeneca's Imfinzi immunotherapy combo fails to show benefit in lung cancer pharmafile
November 19, 2018
AstraZeneca has revealed that its immunotherapy combo of Imfinzi (durvalumab) and tremelimumab failed to meet its primary endpoint in a recent
AstraZeneca’s Imfinzi alone and in combination fails in Stage IV lung cancer trial pharmaceutical-technology
November 19, 2018
AstraZeneca has announced its Phase III MYSTIC trial of Imfinzi alone and Imfinzi combined with tremelimumab in untreated non-small cell lung cancer (NSCLC) patients failed to meet its primary endpoint.
AstraZeneca's Imfinzi immunotherapy combo fails to show benefit in lung cancer pharmafile
November 19, 2018
AstraZeneca has revealed that its immunotherapy combo of Imfinzi (durvalumab) and tremelimumab failed to meet its primary endpoint in a recent Phase 3 trial in the treatment
FDA Approves Lorlatinib americanpharmaceuticalreview
November 07, 2018
FDA Approves Lorlatinib
Yuhan licences lung cancer asset to Janssen in $1.25bn deal pharmaceutical-technology
November 06, 2018
South Korean pharmaceutical company Yuhan has signed a licensing and cooperation agreement valued at up to $1.25bn with Janssen Biotech to out-license a lung cancer drug candidate called Lazertinib.
Shares in Mirati plummet after disappointing Phase II trial pharmafile
November 01, 2018
Shares in the California-based biotech Mirati Therapuetics plummeted on Monday after the company released disappointing results from their Phase II study of the experimental drug sitravatinib...
Preliminary NICE ‘no’ for Takeda’s Alunbrig pharmatimes
October 11, 2018
Draft guidelines from the National Institute for Health and Care Excellence do not recommend NHS funding for Takeda’s lung cancer drug Alunbrig.
Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC worldpharmanews
September 28, 2018
The survey results will be presented as a late-breaking abstract (P3.01-108) at the 2018 World Conference on Lung Cancer (WCLC) in Toronto, Canada.
Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC worldpharmanews
September 28, 2018
Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make informed decisions on how to sequence treatments for patients with epidermal growth fact

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page